Clinical Trial Update: GTA-Glyceryltriacetate for Canavan Disease [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for GTA-Glyceryltriacetate in Canavan disease; the trial status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Canavan Disease

Drugs mentioned

• GTA-Glyceryltriacetate (glyceryltriacetate)

Snippet

Sponsor: Sheba Medical Center | Conditions: Infantile Canavan Disease, Deficiency Disease, Aspartoacylase | Phase 1 | Status: UNKNOWN